Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab.

"Declarations Conflicts of interestGH is the founder and previous shareholder in the company manufacturing the GoTreatIT Rheuma tool. AHP, MK and KŁ have declared no conflicts of interest. Compliance with ethical standardsThe study was approved by the regional ethical committee (REC; Regional etisk komite Midt-Norge 2010/3078). Regional Committees for Medical and Health Research Ethics—REC Central (REK; Regionale komiteer for medisinsk og helsefaglig forskningsetikk) waived the need for informed consent from patients, as all data were anonymised and collected as part of routine clinical care. The study complied with the Declaration of Helsinki. Conflicts of interest GH is the founder and previous shareholder in the company manufacturing the GoTreatIT Rheuma tool. AHP, MK and KŁ have declared no conflicts of interest."

"Funding No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article."